mAb Development

May 01, 2008
BioPharm International
By BioPharm International Editors
Understanding the impact on process performance.
Apr 01, 2008
BioPharm International
The book is a useful, comprehensive, and truly an excellent reference source of biopharmaceutical information.
Mar 02, 2008
BioPharm International
When platform processes are applied to fusion molecules, innovation and flexibility are needed.
Mar 02, 2008
BioPharm International
If certain engineering challenges can be addressed, precipitation may prove to be a valuable tool for antibody purification.
Mar 02, 2008
BioPharm International
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
Mar 02, 2008
BioPharm International
An alternative approach to traditional Protein A schemes is comparable in overall efficiency, product recovery, and quality.
Mar 02, 2008
BioPharm International
Manufacturing challenges surround the use of IgM monoclonal antibodies, but these can be overcome with current technology.
Oct 09, 2007
BioPharm International
By BioPharm International Editors
The US Patent & Trademark Office has issued the fifth US patent to MorphoSys AG (Munich, Germany) stemming from MorphoSys’s base HuCAL (human combinatorial antibody library) patent family, providing extended protection to MorphoSys’s core technology.
Oct 09, 2007
BioPharm International
By BioPharm International Editors
Crucell N.V. (Leiden, the Netherlands) has discovered a set of human monoclonal antibodies (MAbs) that work to neutralize and protect against H5N1.
Oct 01, 2007
BioPharm International
In one series of experiments, the glycosylation site of IgG1 was removed and an IgA glycosylation site was introduced—resulting in a total loss of biological function.
native1_300x100
lorem ipsum